Jaypirca® (Pirtobrutinib) Approved In China For A New Indication In Chronic Lymphocytic Leukemia (Cll) /Small Lymphocytic Lymphoma (Sll) Across All Lines Of Therapy

Innovent Biologics, Inc. HKEX:1801